Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management.

Content Provider	Europe PMC
Author	Al-Janabi, A Yiu, Z Z N
Copyright Year	2022
Abstract	Abstract Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In addition to treatment effectiveness, it is important to define and understand the long-term risks of biologic therapy in order to guide therapy selection and minimise these risks for patients where possible. This review article summarises available evidence from trial data, observational studies and pharmacovigilance registries to explore key long-term risks of biologic treatment, and how these risks might be managed in clinical practice.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8747772&blobtype=pdf
Page Count	14
Volume Number	12
PubMed Central reference number	PMC8747772
PubMed reference number	35024352
Journal	Psoriasis: Targets and Therapy [Psoriasis (Auckl)]
e-ISSN	2230326X
DOI	10.2147/ptt.s328575
Language	English
Publisher	Dove
Publisher Date	2022-01-06
Access Restriction	Open
Rights License	This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2022 Al-Janabi and Yiu.
Subject Keyword	psoriasis biologics therapeutics safety
Content Type	Text
Resource Type	Article
Subject	Dermatology